Livmarli Dosage/Direction for Use

Dosing: The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before a meal in the morning. Start dosing at 190 mcg/kg administered orally once daily; after one week, increase to 380 mcg/kg once daily, as tolerated. The maximum daily dose volume for patients above 70 kg is 3 mL or 28.5 mg per day. Refer to the dosing by weight guidelines presented in Table 2. (See Table 2.)

Click on icon to see table/diagram/image

Missed Dose: If a dose is missed, it should be taken as soon as possible within 12 hours of the time it is usually taken, and the original dosing schedule should be resumed. If a dose is missed by more than 12 hours, the dose can be omitted and the original dosing schedule resumed.
Important Administration Instructions: Administer LIVMARLI 30 minutes before a meal in the morning [see Pharmacology: Pharmacokinetics under Actions].
For patients taking bile acid binding resins, take LIVMARLI at least 4 hours before or 4 hours after taking a bile acid binding resin [see Effects of Other Drugs on LIVMARLI under Interactions].
A calibrated measuring device (0.5 mL, 1 mL or 3 mL oral dosing dispenser) are provided to measure and deliver the prescribed dose accurately with each bottle of LIVMARLI. After opening the LIVMARLI bottle, store below 30°C and discard any remaining LIVMARLI after 100 days.
Dose Modification for Management of Adverse Events: Establish the baseline pattern of variability of liver tests prior to starting LIVMARLI, so that potential signs of liver injury can be identified. Monitor liver tests (e.g., ALT [alanine aminotransferase], AST [aspartate aminotransferase], TB [total bilirubin]), DB [direct bilirubin] and International Normalized Ratio [INR]) during treatment with LIVMARLI. Interrupt LIVMARLI if new onset liver test abnormalities occur in the absence of other causes. Once the liver test abnormalities either return back to baseline values or stabilize at a new baseline value, consider restarting LIVMARLI at 190 mcg/kg, and increase to 380 mcg/kg as tolerated. Consider discontinuing LIVMARLI permanently if liver test abnormalities recur or symptoms consistent with clinical hepatitis are observed [see Liver Test Abnormalities under Precautions].
LIVMARLI has not been studied in patients with hepatic decompensation. Discontinue LIVMARLI permanently if a patient experiences a hepatic decompensation event (e.g., variceal hemorrhage, ascites, hepatic encephalopathy).